The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient.

Abstract

BACKGROUND:

Numerous cases with ocular toxicity secondary to tamoxifen have been reported, and became more apparent with keratopathy, cataract, optic neuritis, macular holes, crystalline retinopathy with or without cystoid macular edema (CME). Withdrawing tamoxifen with the approval of the oncologist is the major treatment for cases with tamoxifen-induced retinopathy.

CASE PRESENTATION:

We herein reported a patient with a two-year history of painless and reduced visual acuity in both eyes who received tamoxifen therapy for 6 years. Tamoxifen-induced rentinopathy with CME showed significant development even though the patient has already discontinued tamoxifen treatment for 6 months. Anatomic improvements after intravitreal ranibizumab injection in both eyes were significant but were temporary. Surprisingly, CME in both eyes has been resolved spontaneously after 10 months in the penultimate visit without any therapy.

CONCLUSION:

Intravitreal ranibizumab injection temporarily improved the anatomy of the eyes in a case with tamoxifen-induced CME, and only tamoxifen withdrawal can bring a sustained effect.

• Authors: Chuanyu Li, Jun Xiao, He Zou, Bo Yang, Lifu Luo
• Journal: BMC ophthalmology (BMC Ophthalmol) Vol. 21 Issue 1 Pg. 201 (May 07 2021) ISSN: 1471-2415 [Electronic] England
• PMID: 33962570 (Publication Type: Journal Article)

Chemical References

• Tamoxifen
• Bevacizumab
• Ranibizumab

Topics

• Bevacizumab (therapeutic use)
• Humans
• Intravitreal Injections
• Macular Edema (chemically induced, drug therapy)
• Ranibizumab (therapeutic use)
• Tamoxifen (adverse effects)
• Tomography, Optical Coherence
• Visual Acuity